MMRF PRESS RELEASES
Data from eight clinical trials facilitated by the Multiple Myeloma Research Consortium (MMRC) presented at the American Society of Hematology (ASH) annual meeting
Norwalk, CT — December 10, 2008
The Multiple Myeloma Research Consortium (MMRC) today announced that data from eight clinical trials in its portfolio as well as findings from the MMRC Multiple Myeloma Genomics Initiative were presented at the American Society of Hematology's (ASH) 50th Annual Meeting and Exposition held Dec. 6-9, 2008, in San Francisco, Calif.
"We are proud that data from eight clinical trials that the MMRC has helped to advance in partnership with the sponsors and MMRC Member Institutions were selected for presentation at the prestigious ASH annual meeting,"said Susan Kelley, MD, Chief Medical Officer of the MMRC. "This recognition provides an important validation of our consortium research model and our ongoing efforts to bring the next generation of treatments to patients with multiple myeloma."
To date the MMRC, in collaboration with its partners in academia and the biotech and pharmaceutical industries, has helped to advance 16 Phase I and II clinical trials, eight of which were the subject of oral and poster presentations at the annual ASH meeting:
- (Abstract 864) Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
- (Abstract 865) Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
- (Abstract 2270) Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma
- (Abstract 2774) A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma
- (ASH 2781) A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
- (Abstract 3691) Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
- (Abstract 3696) Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
- (Abstract 3706) A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
In addition, data from the MMRC Multiple Myeloma Genomics Initiative, an innovative genome-mapping program conducted in partnership with Eli and Edythe L. Broad Institute of MIT and Harvard and The Translational Genomics Research Institute, was presented by Michael Chapman, PhD, of the Broad Institute, in an oral presentation (abstract 497), "Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease."
"As presented in the oral session, the MMRC Multiple Myeloma Genomics Initiative work has now more than doubled the number of known DNA alterations and potential candidate genes in multiple myeloma. It is gratifying to see the progress for patients being made through this important project" said Louise M. Perkins, PhD, Chief Scientific Officer of the MMRF.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Foundation (MMRC), a 509a3 organization, was founded in 2004 by Kathy Giusti, a myeloma patient and Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF), to champion collaboration with and integration across academia and industry — while introducing high levels of accountability into the process from all involved in research and development.
At the core of the MMRC model is an Executive Committee, based in Norwalk, Conn., which provides strategic scientific and clinical oversight of the MMRC's drug development projects. The MMRC's Member Institutions include prominent multiple myeloma clinical research centers in North America: City of Hope (Duarte, Calif.), Dana-Farber Cancer Institute (Boston, Mass.), Emory University's Winship Cancer Institute,(Atlanta, Ga.), the Cancer Center at Hackensack University Medical Center (Hackensack, N.J.), H. Lee Moffitt Cancer Center & Research Institute (Tampa, Fla.) Indiana University (Indianapolis, Ind.), Mayo Clinic (Minnesota and Arizona), Ohio State University (Columbus, Ohio), St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York (New York, N.Y.), University Health Network (Princess Margaret Hospital, Toronto, Ontario, Canada), University of Chicago (Chicago, Ill.), University of Michigan (Ann Arbor, Mich.), University of California — San Francisco (San Francisco, Calif.), and Washington University (St Louis, Mo.). The MMRC's collaborative model also includes a Tissue and Data Bank, which serve as a "bridge" between laboratory and clinical research conducted by the MMRC members and a vital resource in advancing MMRC clinical trials and correlative science studies.
As a results-driven organization, the MMRC has, to date, partnered with pharmaceutical and academic sponsors to facilitate 16 Phase I and II clinical trials of the most promising, novel, investigational compounds and new potential combination treatment approaches for myeloma. MMRC clinical trials are designed to include correlative studies, to better understand what drugs are most effective in treating various sub-groups of patients with myeloma, laying the foundation for the eventual development of additional treatment options for patients with myeloma.